News & Updates

Breast cancer survival has been improving greatly over the last 14 years, an effect attributable to advancements in systemic therapy, a recent Korea study has found.

Meat eaters can rejoice in knowing that they are not at greater risk of developing total gastric cancer, according to a cohort study in Japan.

Androgen deprivation therapy (ADT) does not seem to aggravate the likelihood of major adverse cardiovascular events (MACEs) in prostate cancer patients after curative radiotherapy (RT), according to a recent Singapore study.

Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.

Treatment with the combination of fulvestrant plus sapanisertib yields a numerical increase in progression-free survival in patients with ER-positive, HER2-negative advanced or metastatic breast cancer as compared with the use of fulvestrant alone, according to the results of a phase II trial. However, the combination is associated with increased toxicity.

A prospective clinical study conducted by the Hong Kong Baptist Hospital in collaboration with the Hong Kong Polytechnic University has demonstrated the feasibility of implementing respiratory-gated PET-CT for liver malignancies with improved image quality compared with ungated scans.

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.